Takeda shareholders fear dilution, debt from Shire deal pose ‘high risks,’ demand shareholders vote on it

Takeda’s long-sought $62 billion acquisition bid for Shire has launched the Japanese drugmaker into the big leagues, but it hasn’t quite been embraced by investors. The company’s shares have lost more than 20% of their value since late March, when Takeda was preparing its first of what ended up being five bids for Shire.